Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just pop in to say that Glen there are actually 2 websites DMTR has. Google search takes you to https://www.deepmattergroup.com/.. and if you go to top right this takes you to https://www.deepmatter.io/. hope that helps. BTW as I cant be bothered putting message in Sng board (I am a LTH of the company) because of over crowding and as some are here, I would like to say belated congrats to all.. worth all the waiting and research.
Last point, I cant help myself to say this but as I predicted before SNG001 efficacy was indeed 75% or more.
GLA
with all the posts today I somewhat thought about Old timer and Arnie. at least they have sense of humor . I wonder if they are still around?
P S still holding and please lighten up guys sp is up even though its down today.
GLA
I am not complaining at all. Im just saying that you cant state timelines without fulfilling them. In march the CEO says its 8 weeks and got fast-track, Then he says on LBC is end of June and now says its July. These are three statements. you either have to deliver on one of them or not.
i think its because of CEO's briefings. in March he said the trial is 8 weeks, then end of June and now says its July. You cant run business like this. Constantly changing timelines is not good. Anyway I,m holding until the result.
GLA
Magic your the best. I could kiss you.
Amazing presentation. So informative.
Thank you and to all contributors esp paddy, tig, schiemel, mushroom. Ot (is banned I heard) and coach and others who have contributed so much on this board. Thank you very much.
ATB
I've been reading posts and you seem to imply something, the I read your posts seemingly trying to pinpoint something per your Canadian friend.
are you alluding to this https://en.wikipedia.org/wiki/Dome_Mine ?
GLA
Thus, nebulized IFN-ß treatment is the first therapy acting on the causal viral pathway that seems able to prevent worsening of asthma symptoms if administered shortly after patients become aware of a cold developing
Additionally, IFN-ß treatment resulted in a modest, but significant, induction of systemic innate immune responses as judged by the genome-wide gene expression analysis of blood cells, which showed significant differences in genes involved in type I IFN signaling. Together with the sustained and marked elevation of CXCL10 protein levels in blood, this suggests that treatment with IFN-ß enhanced innate immunity, which in turn improved the clinical outcome of the cold. The trend toward reduced load of RV in sputum observed with treatment suggests that better antiviral defenses may result in faster clearance of RVs. Further studies, including analysis of other viruses, are required for more definitive proof.
In summary, this study suggests for the first time that administration of IFN-ß by inhalation can enhance innate immunity both locally within the lungs and, to a lesser extent, systemically, thereby compensating for the IFN-ß deficiency that we have previously demonstrated ex vivo in the epithelium of patients with moderate-severe asthma (6). The possible beneficial clinical effect of treatment seen in patients with moderate-severe asthma that was associated with this enhancement suggests that this treatment may impact favorably on cold-induced asthma exacerbations. The trial was designed and powered on the basis of the entire mITT patient population; therefore, further adequately powered studies focusing on more difficult-to-treat people with asthma are now needed to test the hypothesis that IFN-ß is effective in this high-risk patient population
GLA
Snippets of conclusion from this study:
https://www.atsjournals.org/doi/full/10.1164/rccm.201312-2235OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&
I only copied the ones that I understood and the significant details from the “Discussion” page which I thought were really promising.
The study suggests that, when given at the time of reporting an URTI, inhaled IFN-ß can ameliorate the way the airways of patients with asthma respond to viral infection. Although the trial did not show a positive effect on ACQ-6, the primary outcome, treatment with IFN-ß, had a positive effect on morning lung function (PEF) and, in parallel, enhanced innate immunity both systemically and in the lungs as assessed by serum CXCL10 concentration and induction of genes for antiviral biomarkers CXCL10, Mx1, and OAS1 in induced sputum. This was associated with reduced proinflammatory cytokines in sputum and a trend toward reduced sputum RV load. Analysis of the moderate to severe people with asthma (Step 4 and 5 according to BTS guidelines) suggested a beneficial clinical effect of treatment, as shown by a mean 0.63 reduction in ACQ-6 score in patients treated with IFN-ß (P = 0.004 as compared with those on placebo) that is widely viewed as being clinically significant. Genome-wide gene expression analysis using circulating blood cells from this subset of patients also showed that treatment with nebulized IFN-ß enhanced systemic innate immunity.
The study, therefore, suggests that IFN-ß treatment may be most appropriate for the more difficult to control people with asthma in whom the underlying disease process is likely to be more severe, thus requiring more intensive treatment, and in whom the risks of exacerbations, health impact, and treatment costs are greatest (24).